Arrowhead Pharmaceuticals Croissance future
Future contrôle des critères 2/6
Arrowhead Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 24.1% et de 20.5% par an respectivement. Le BPA devrait croître de de 24% par an. Le rendement des capitaux propres devrait être -60.6% dans 3 ans.
Informations clés
24.1%
Taux de croissance des bénéfices
23.99%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 24.7% |
| Taux de croissance des recettes | 20.5% |
| Rendement futur des capitaux propres | -60.57% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 08 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour de l'analyse • May 07
ARWR: Cardiometabolic RNAi Data And Licensing Progress Will Drive Future Repricing
Analysts have raised their Arrowhead Pharmaceuticals price target by $12 to $110, citing updated assumptions for a less severe revenue contraction, higher projected profit margins, and a lower forward P/E estimate in recent research. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals has reflected a mix of caution and renewed optimism, with several bullish analysts focusing on price target changes, upgrades, and the implications for valuation and execution risk.
Mise à jour de l'analyse • Apr 21
ARWR: Wave Data Concerns Will Test Sustainability Of Recent Share Price Rebound
Arrowhead Pharmaceuticals' analyst price target has edged higher by about $0.26 to $42.57, with analysts pointing to updated views on profit margins and P/E assumptions following a mix of recent target raises and trims across the Street. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals reflects a split view, with some firms lifting targets sharply and others trimming expectations.Mise à jour de l'analyse • Apr 06
ARWR: RNAi Obesity And Cardiometabolic Data Will Drive Future Repricing
Narrative update on Arrowhead Pharmaceuticals The consensus analyst price target for Arrowhead Pharmaceuticals has been adjusted to $110. This reflects mixed recent research that pairs questions around Wave Life Sciences data with higher targets from several firms citing early obesity program results and the Redemplo launch.Seeking Alpha • Mar 26
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
Summary Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial stage, with its first approval for plozasiran in FCS. ARWR's valuation reflects a 5% downside, 10-15% base case upside, and up to 40% bull case upside, supporting a cautious buy rating. The investment thesis centers on a robust RNAi platform, late-stage cardiometabolic franchise, and significant near-term catalysts, notably SHTG phase 3 data. Risks include execution on commercialization, reliance on milestone payments, and potential dilution if revenue growth lags expectations. Read the full article on Seeking AlphaMise à jour de l'analyse • Mar 23
ARWR: Obesity RNAi Data And Cardiometabolic Franchise Will Drive Future Repricing
Analysts have updated their views on Arrowhead Pharmaceuticals with a revised blended price target of $110. This reflects mixed shifts in assumptions around discount rate, revenue growth, profit margins and future P/E after recent obesity and cardiometabolic data, as well as the Redemplo launch.Mise à jour de l'analyse • Mar 09
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Price Rebound
Analysts have reduced their blended price target on Arrowhead Pharmaceuticals by about $2 to reflect a lower fair value estimate of $42.31. This incorporates more cautious assumptions on near term revenue growth and margins, even as recent research notes highlight supportive early obesity data and emerging cardiometabolic opportunities.Mise à jour de l'analyse • Feb 22
ARWR: Obesity And Cardiometabolic Pipeline Progress Will Drive Future Repricing
Narrative Update: Arrowhead Pharmaceuticals The updated analyst price framework for Arrowhead Pharmaceuticals keeps fair value at $110 while trimming implied future P/E assumptions, reflecting analysts' mixed but generally constructive reaction to recent obesity and cardiometabolic data and the Redemplo launch. Analyst Commentary Recent research updates on Arrowhead Pharmaceuticals cluster around two themes you should keep in mind: confidence in the obesity and cardiometabolic pipeline, and growing interest in the early commercial rollout of Redemplo.Article d'analyse • Feb 12
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) earnings announcement last week was disappointing for investors...Mise à jour de l'analyse • Feb 08
ARWR: Obesity Pipeline Progress Will Drive Future Repricing In My View
Analysts raised their fair value estimate for Arrowhead Pharmaceuticals to $110 from $80 as they incorporate updated assumptions on Redemplo's launch, initial obesity pipeline data, and a lower projected future P/E multiple, while also reflecting slightly higher risk and more conservative expectations for revenue growth. Analyst Commentary Bullish analysts are leaning into Arrowhead's transition from a pure development story toward one with its first approved product and an emerging obesity pipeline, and they are adjusting their models to reflect both assets.Mise à jour de l'analyse • Jan 25
ARWR: Early Obesity RNAi Data Will Challenge Durability Of Recent Share Repricing
Narrative update on Arrowhead Pharmaceuticals The updated analyst price target for Arrowhead Pharmaceuticals shifts to reflect a fair value of $44.02. Analysts point to Redemplo's approval and launch, early data from the ARO INHBE and ARO ALK7 obesity programs, and increased confidence in the pipeline as key factors in their revised outlook.Mise à jour de l'analyse • Jan 11
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Repricing
Arrowhead Pharmaceuticals' analyst fair value estimate moved from $17.00 to about $44.94, as analysts cited early obesity trial data for ARO INHBE and ARO ALK7, validation of the TRiM RNAi platform, and the first FDA approval of Redemplo as key reasons for higher price targets in the US$80 range. Analyst Commentary Street research around Arrowhead has tilted more constructive around the obesity franchise, with multiple firms lifting their fair value estimates into the US$80 range after the initial ARO INHBE and ARO ALK7 data.
Mise à jour de l'analyse • Dec 18
ARWR: Upcoming SHTG Readouts Will Temper Optimism Despite Recent Cardiometabolic Progress
Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages. Analyst Commentary Bullish analysts view Redemplo's FCS approval as a key de-risking event that supports higher valuation multiples and justifies recent price target increases into the high $40s to low $60s range.Mise à jour de l'analyse • Dec 04
ARWR: Upcoming SHTG Data Will Likely Undermine Optimistic Cardiometabolic Expectations
Analysts have nudged their average price target on Arrowhead Pharmaceuticals higher to about $58 from $55, citing the FDA approval of Redemplo, expectations for a broader sHTG label, and underappreciated long term cost and margin advantages. Analyst Commentary Research coverage following the Redemplo approval has generally tilted positive, with several firms lifting their price targets and highlighting both the commercial opportunity in sHTG and Arrowhead's long term margin profile.Article d'analyse • Dec 02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have continued their recent momentum with a 33% gain in the last...Mise à jour de l'analyse • Nov 20
ARWR: FDA Milestone Will Drive Cost Advantage In Cardiometabolic Markets
Analysts have raised Arrowhead Pharmaceuticals' fair value estimate from $47.50 to $55.00 per share after the FDA approved Redemplo and expressed increased confidence in the company's commercial execution and cost advantages. Analyst Commentary Following the recent FDA approval of Redemplo, analysts have provided updated perspectives on Arrowhead Pharmaceuticals' valuation and prospects.Mise à jour de l'analyse • Nov 06
ARWR: Expect Cost Efficiency To Drive Competitive Advantage In Upcoming Metabolic Trials
Analysts have significantly raised their price target for Arrowhead Pharmaceuticals, increasing it from $38 to $61 per share. They cite structural cost advantages and an underappreciated long-term gross margin potential as key factors for this change.Mise à jour de l'analyse • Oct 22
Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships
Arrowhead Pharmaceuticals' analyst price target has been raised from $45 to $47.50 per share. Analysts highlight the company's structural cost advantages and improved margin outlook.Article d'analyse • Oct 07
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You
Despite an already strong run, Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have been powering on, with a...Mise à jour de l'analyse • Oct 05
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
Analysts have slightly lowered their price target for Arrowhead Pharmaceuticals from $46.15 to $45.00, citing ongoing concerns following recent strategic divestitures by partners and modest shifts in the company's projected financials. Analyst Commentary Recent analyst research provides a mixed outlook for Arrowhead Pharmaceuticals following notable events involving partner Sarepta Therapeutics.Mise à jour de l'analyse • Sep 08
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
The consensus price target for Arrowhead Pharmaceuticals has increased modestly as its Future P/E has risen and Net Profit Margin has declined, resulting in a new analyst fair value of $46.15. What's in the News Arrowhead Pharmaceuticals announced a major global licensing and collaboration agreement with Novartis for ARO-SNCA, its preclinical siRNA therapy for synucleinopathies such as Parkinson’s Disease; the deal includes a $200 million upfront payment to Arrowhead, potential milestones up to $2 billion, and future royalties, with closing expected in the second half of 2025 (Key Developments).Article d'analyse • Aug 21
Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
The Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) share price has done very well over the last month, posting an...Nouvelle analyse • May 18
Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles
Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.Article d'analyse • May 14
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders are no doubt pleased to see that the share price has...Seeking Alpha • Mar 21
Arrowhead Pharmaceuticals Is Finally Arriving
Summary Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028. Despite competition from Ionis' Olezarsen, ARWR's promising data and strategic partnerships make it a compelling long-term investment in RNAi therapeutics. Read the full article on Seeking AlphaSeeking Alpha • Feb 19
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Summary Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent. Plozasiran is ready to launch for the treatment FCS, two obesity programs will be in the clinic this year, and new programs are coming into the clinic. Stock could remain under pressure in the near-term, but improved financial outlook and pipeline progress put the company in a strong position to deliver long-term shareholder gains. Read the full article on Seeking AlphaSeeking Alpha • Feb 10
Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns
Summary Arrowhead Pharmaceuticals has an interesting TRiM RNAi platform that could eventually let it tap into large TAMs across several markets. They recently received the FDA NDA acceptance for Plozasiran, which is probably one of its most bullish events at this point. In addition, they secured a large deal with SRPT. Moreover, ARWR does have a diversified pipeline of drugs targeting lipid disorders, obesity, cardiovascular, and pulmonary conditions. Unfortunately, I have some valuation concerns. ARWR trades at a high P/S, and its cash burn remains elevated. This could become an issue if they have any setbacks. This is why I lean neutral on ARWR for now, giving it a “Hold.” But I do believe the stock could be a great buy on dips if they happen. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 9/30/2028 | 566 | -417 | -185 | -251 | 10 |
| 9/30/2027 | 329 | -596 | -385 | -445 | 13 |
| 9/30/2026 | 466 | -434 | -189 | -316 | 13 |
| 3/31/2026 | 622 | -301 | -51 | -36 | N/A |
| 12/31/2025 | 1,091 | 202 | 322 | 339 | N/A |
| 9/30/2025 | 829 | -2 | 157 | 180 | N/A |
| 6/30/2025 | 573 | -148 | -18 | 22 | N/A |
| 3/31/2025 | 545 | -144 | 10 | 61 | N/A |
| 12/31/2024 | 3 | -640 | -572 | -491 | N/A |
| 9/30/2024 | 4 | -599 | -604 | -463 | N/A |
| 6/30/2024 | 20 | -539 | -533 | -352 | N/A |
| 3/31/2024 | 35 | -471 | -470 | -257 | N/A |
| 12/31/2023 | 182 | -297 | -403 | -196 | N/A |
| 9/30/2023 | 241 | -205 | -331 | -154 | N/A |
| 6/30/2023 | 256 | -181 | -342 | -197 | N/A |
| 3/31/2023 | 273 | -150 | -353 | -245 | N/A |
| 12/31/2022 | 278 | -155 | -236 | -150 | N/A |
| 9/30/2022 | 243 | -176 | -189 | -136 | N/A |
| 6/30/2022 | 250 | -154 | -120 | -91 | N/A |
| 3/31/2022 | 263 | -112 | -75 | -52 | N/A |
| 12/31/2021 | 144 | -183 | 124 | 149 | N/A |
| 9/30/2021 | 138 | -141 | 148 | 171 | N/A |
| 6/30/2021 | 108 | -126 | 167 | 184 | N/A |
| 3/31/2021 | 89 | -110 | 165 | 181 | N/A |
| 12/31/2020 | 80 | -103 | -123 | -111 | N/A |
| 9/30/2020 | 88 | -85 | -108 | -96 | N/A |
| 6/30/2020 | 124 | -24 | -89 | -71 | N/A |
| 3/31/2020 | 139 | 10 | -46 | -27 | N/A |
| 12/31/2019 | 164 | 53 | N/A | -19 | N/A |
| 9/30/2019 | 169 | 68 | N/A | 173 | N/A |
| 6/30/2019 | 137 | 46 | N/A | 157 | N/A |
| 3/31/2019 | 95 | 10 | N/A | 132 | N/A |
| 12/31/2018 | 47 | -29 | N/A | 136 | N/A |
| 9/30/2018 | 16 | -54 | N/A | -47 | N/A |
| 6/30/2018 | 14 | -54 | N/A | -54 | N/A |
| 3/31/2018 | 22 | -44 | N/A | -50 | N/A |
| 12/31/2017 | 31 | -35 | N/A | -49 | N/A |
| 9/30/2017 | 31 | -34 | N/A | -24 | N/A |
| 6/30/2017 | 23 | -46 | N/A | -25 | N/A |
| 3/31/2017 | 13 | -60 | N/A | -33 | N/A |
| 12/31/2016 | 4 | -75 | N/A | -33 | N/A |
| 9/30/2016 | 0 | -82 | N/A | -64 | N/A |
| 6/30/2016 | 0 | -84 | N/A | -66 | N/A |
| 3/31/2016 | 0 | -81 | N/A | -61 | N/A |
| 12/31/2015 | 0 | -89 | N/A | -63 | N/A |
| 9/30/2015 | 0 | -92 | N/A | -66 | N/A |
| 6/30/2015 | 0 | -90 | N/A | -65 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ARWR devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ARWR devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ARWR devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ARWR ( 20.5% par an) devrait croître plus rapidement que le marché US ( 11.5% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ARWR ( 20.5% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ARWR devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/10 22:59 |
| Cours de l'action en fin de journée | 2026/05/08 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/09/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Arrowhead Pharmaceuticals, Inc. est couverte par 29 analystes. 13 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ying Huang | Barclays |
| William Pickering | Bernstein |
| Jason Matthew Gerberry | BofA Global Research |